Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) have received an average recommendation of “Hold” from the six ratings firms that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $72.00.

A number of research firms have weighed in on ANIP. Canaccord Genuity set a $70.00 price target on ANI Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 9th. Cantor Fitzgerald set a $74.00 price target on ANI Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, November 6th. BidaskClub downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 1st. Finally, ValuEngine raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 23rd.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of ANI Pharmaceuticals by 7.3% in the 2nd quarter. BlackRock Inc. now owns 1,391,174 shares of the specialty pharmaceutical company’s stock valued at $92,931,000 after buying an additional 94,786 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of ANI Pharmaceuticals by 6.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 511,881 shares of the specialty pharmaceutical company’s stock valued at $28,941,000 after buying an additional 32,556 shares during the last quarter. Nomura Holdings Inc. boosted its holdings in shares of ANI Pharmaceuticals by 10.0% in the 2nd quarter. Nomura Holdings Inc. now owns 310,115 shares of the specialty pharmaceutical company’s stock valued at $20,716,000 after buying an additional 28,134 shares during the last quarter. First Manhattan Co. raised its stake in ANI Pharmaceuticals by 48.0% in the 3rd quarter. First Manhattan Co. now owns 215,695 shares of the specialty pharmaceutical company’s stock valued at $12,195,000 after acquiring an additional 70,000 shares during the period. Finally, Renaissance Technologies LLC raised its stake in ANI Pharmaceuticals by 2.9% in the 3rd quarter. Renaissance Technologies LLC now owns 178,400 shares of the specialty pharmaceutical company’s stock valued at $10,087,000 after acquiring an additional 5,100 shares during the period. 62.29% of the stock is owned by institutional investors.

NASDAQ:ANIP traded down $0.05 during trading hours on Thursday, reaching $53.51. 3,570 shares of the stock were exchanged, compared to its average volume of 76,934. ANI Pharmaceuticals has a twelve month low of $48.40 and a twelve month high of $74.70. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 1.04. The company has a market cap of $627.54 million, a P/E ratio of 14.74 and a beta of 2.64.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.12. ANI Pharmaceuticals had a return on equity of 28.39% and a net margin of 0.23%. The firm had revenue of $50.70 million during the quarter, compared to the consensus estimate of $50.97 million. During the same quarter in the prior year, the firm posted $1.11 EPS. The business’s revenue was up 5.3% on a year-over-year basis. As a group, analysts anticipate that ANI Pharmaceuticals will post 4.54 earnings per share for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Recommended Story: Cost of Capital

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.